A carregar...
Ponatinib: Accelerated Disapproval
“Accelerated Approval” (AA) has addressed important unmet needs in oncology. However, it is only justified if the drug fills a serious gap because such approval entails risk and leads to marketing based on incomplete information about toxicity, dose, and therapeutic potential. Furthermore, the polic...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4524765/ https://ncbi.nlm.nih.gov/pubmed/26173838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0253 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|